TITLE

The wonder drug that wasn't

PUB. DATE
August 1993
SOURCE
U.S. News & World Report;8/2/93, Vol. 115 Issue 5, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports that the elevation of so-called convergent combination therapy developed by Yung-Kang Chow, a young Harvard medical student, is a cautionary tale. 400-person clinical trial called into question the therapy; Idea of using a cocktail of different drugs against HIV is still valid; Experimental compound nevirapine could slow or halt the virus; Details.
ACCESSION #
9307270084

 

Related Articles

  • Eptacog-α/factor VIII inhibitor bypassing fraction.  // Reactions Weekly;8/20/2011, Issue 1365, p19 

    The article describes the cases of four patients who experienced hypersensitivity and elevated D-dimer levels while receiving sequential combined bypassing therapy with regimens of eptacog-α and factor VIII inhibitor bypassing fraction.

  • Tazarotene triumphs most often when used in combo therapies. Nemec, John // Dermatology Times;Jan2001, Vol. 22 Issue 1, p24 

    Reports the efficiency of utilizing tazarotene in combination therapy for psoriasis and acne medications in Geneva, Switzerland. Use of potent steroid and ultraviolet B phototherapy in combo therapy; Effect of retinoid on psoriasis plaque elevation and scaling; Potential uses of tazarotene.

  • ASB seeks comments on Business Combinations Exposure Drafts.  // Accountancy Ireland;Oct2005, Vol. 37 Issue 5, p30 

    Reports that the Accounting Standards Board (ASB) has published FRED 36 "Business Combinations" and FRED 37 & 38 "Intangible Assets" and "Impairment of Assets." Strategy of ASB for convergence with International Financial Reporting Standards; Issues arising from the convergence; Call for...

  • Progress and setbacks on the AIDS front.  // U.S. News & World Report;6/14/93, Vol. 114 Issue 23, p34 

    Comments on issues to be discussed at the upcoming AIDS conference in Berlin. Convergent combination therapy; Concorde trial; Vaccines; Conference sites.

  • Hidden mutation kills off triple drug HIV therapy. Brown, Phyllida // New Scientist;7/31/93, Vol. 139 Issue 1884, p6 

    Reports on the discovery of a flaw in medical student Yung-Kang Chow's claims that a combination of drugs could force HIV to `mutate itself to death'. Basis of Chow's claim on convergent combination therapy; Extra undetected mutation in the reverse transcriptase (RT) gene; Results of Sharon...

  • Myopathy induced by statin-ezetimibe combination: Evaluation of potential risk factors. Brahmachari, Ballari; Chatterjee, Suparna // Indian Journal of Pharmacology;Sep/Oct2015, Vol. 47 Issue 5, p563 

    Although both atorvastatin and ezetimibe may cause myopathy, statin-induced myopathy is less likely at low doses, and ezetimibe is only rarely reported to induce myopathy. Also, ezetimibe is not usually known to potentiate statin-induced myopathy. We report a case of myalgia with elevated serum...

  • Janumet approved for NHS Scotland.  // GP: General Practitioner;6/11/2010, p4 

    The article reports that diabetes combination therapy called Janumet has been approved for use in Great Britain's National Health Service (NHS) in Scotland.

  • Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia. Khanim, Farhat L.; Hayden, Rachel E.; Birtwistle, Jane; Lodi, Alessia; Tiziani, Stefano; Davies, Nicholas J.; Ride, Jon P.; Viant, Mark R.; Gunther, Ulrich L.; Mountford, Joanne C.; Schrewe, Heinrich; Green, Richard M.; Murray, Jim A.; Drayson, Mark T.; Bunce, Chris M. // PLoS ONE;2009, Vol. 4 Issue 12, p1 

    Background: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have...

  • RP vs. radiation: Combining them may be best option. Gebhart, Fred // Urology Times;4/1/2006, Vol. 34 Issue 4, p14 

    The article reveals that prostatectomy plus radiation therapy may offer the best patient outcomes. It reports on the debate over radical prostatectomy versus radiation therapy for unfavorable-risk prostate cancer. The article discusses radiation therapy advocate Dr. Mack Roach's call for...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics